Skip to content

Study · Randomized controlled trial · 2026

4 results

Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1.

Sattar N, Tchang BG, Vincent RP, Wang H, Murphy M, Dunn JP, Dimitriadis GK, Fraseur Brumm J

Journal of endocrinological investigation4 May 2026

PMID42082865 (opens in a new tab)PMCIDPMC13219146 (opens in a new tab)DOI10.1007/s40618-026-02883-7 (opens in a new tab)PepBankPUB-42082865
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

ObjectiveTo evaluate shifts in waist-to-height ratio (WHtR) categories among adults with obesity or overweight, with or without prediabetes, treated with tirzepatide in the SURMOUNT-1 study.MethodsThis post hoc analysis included 2,538 participants from the SURMOUNT-1 Phase 3, double-blind, randomized, placebo-controlled trial. Adults with BMI ≥ 30 or ≥ 27 kg/m² and at least one obesity-related complication (ORC), excluding diabetes, were randomized to receive once-weekly tirzepatide (5, 10, or 15 mg) or placebo, alongside a reduced-calorie diet and increased physical activity. Participants were grouped by baseline WHtR (≤ 0.49, > 0.49 to ≤ 0.59, > 0.59) according to the National Institute for Health and Care Excellence (NICE) framework. Participants with prediabetes at baseline had additional follow-up data beyond week 72, and shifts in their WHtR categories at week 176 were also included. Change from baseline in WHtR was analyzed using a mixed model for repeated measures (MMRM). Shift tables were used to summarize changes from baseline to post-baseline WHtR category levels.ResultsAt baseline, 89.8% of participants had a WHtR > 0.59, 10.1% had > 0.49 to ≤ 0.59, and 0.1% had ≤ 0.49. After 72 weeks of tirzepatide (10/15 mg), 16.7% of participants achieved a WHtR ≤ 0.49, and 54.7% improved their baseline WHtR category compared to 9.6% with placebo. At 176 weeks, among participants with prediabetes, 12.2% achieved WHtR ≤ 0.49, and 46.4% improved their category with tirzepatide versus 9.3% with placebo.ConclusionsTirzepatide treatment was associated with sustained improvements in WHtR categories, with a greater proportion of participants shifting to a better WHtR category compared to participants treated with placebo. Improved WHtR may be suggestive of lower future cardiometabolic risk. Further analyses of this nature will enhance the understanding and application of WHtR in obesity management across diverse populations.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, 16.7% of participants achieved a waist-to-height ratio of 0.49 or less after 72 weeks of tirzepatide 10/15 mg.

    In plain wordsIn adults with obesity or overweight, 16.7% reached a waist-to-height ratio of 0.49 or less after 72 weeks of tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseParticipants achieving waist-to-height ratio of 0.49 or less at week 72
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10/15 mg · 72 weeksAs given in this study (human).

    Measurements

    proportion with WHtR 0.49 or less
    16.7%
    tirzepatide 10/15 mg, week 72

    Source sentences

    Summary
    After 72 weeks of tirzepatide (10/15 mg), 16.7% of participants achieved a WHtR ≤ 0.49
    2 context sentences
    Summary · context
    This post hoc analysis included 2,538 participants from the SURMOUNT-1 Phase 3, double-blind, randomized, placebo-controlled trial.
    Summary · context
    Adults with BMI ≥ 30 or ≥ 27 kg/m² and at least one obesity-related complication (ORC), excluding diabetes, were randomized to receive once-weekly tirzepatide (5, 10, or 15 mg) or placebo, alongside a reduced-calorie diet and increased physical activity.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, 54.7% improved their waist-to-height ratio category after 72 weeks of tirzepatide 10/15 mg, versus 9.6% with placebo.

    In plain wordsIn adults with obesity or overweight, more people improved their waist-to-height ratio category with tirzepatide (54.7%) than with placebo (9.6%) at 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    IncreaseImprovement in waist-to-height ratio category at week 72
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10/15 mg · 72 weeksAs given in this study (human).

    Measurements

    proportion improving WHtR category
    54.7%
    tirzepatide 10/15 mg
    proportion improving WHtR category
    9.6%
    placebo

    Source sentences

    Summary
    54.7% improved their baseline WHtR category compared to 9.6% with placebo.
    2 context sentences
    Summary · context
    This post hoc analysis included 2,538 participants from the SURMOUNT-1 Phase 3, double-blind, randomized, placebo-controlled trial.
    Summary · context
    Adults with BMI ≥ 30 or ≥ 27 kg/m² and at least one obesity-related complication (ORC), excluding diabetes, were randomized to receive once-weekly tirzepatide (5, 10, or 15 mg) or placebo, alongside a reduced-calorie diet and increased physical activity.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight and prediabetes, 12.2% achieved a waist-to-height ratio of 0.49 or less at 176 weeks with tirzepatide.

    In plain wordsIn adults with obesity or overweight and prediabetes, 12.2% reached a waist-to-height ratio of 0.49 or less at 176 weeks on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseParticipants with prediabetes achieving waist-to-height ratio of 0.49 or less at week 176
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10/15 mg · 176 weeksAs given in this study (human).

    Measurements

    proportion with WHtR 0.49 or less
    12.2%
    tirzepatide, prediabetes, week 176

    Source sentences

    Summary
    At 176 weeks, among participants with prediabetes, 12.2% achieved WHtR ≤ 0.49
    2 context sentences
    Summary · context
    This post hoc analysis included 2,538 participants from the SURMOUNT-1 Phase 3, double-blind, randomized, placebo-controlled trial.
    Summary · context
    Adults with BMI ≥ 30 or ≥ 27 kg/m² and at least one obesity-related complication (ORC), excluding diabetes, were randomized to receive once-weekly tirzepatide (5, 10, or 15 mg) or placebo, alongside a reduced-calorie diet and increased physical activity.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight and prediabetes, 46.4% improved their waist-to-height ratio category at 176 weeks with tirzepatide versus 9.3% with placebo.

    In plain wordsIn adults with obesity or overweight and prediabetes, more people improved their waist-to-height ratio category with tirzepatide (46.4%) than with placebo (9.3%) at 176 weeks.

    Peptide
    Tirzepatide
    Outcome
    IncreaseImprovement in waist-to-height ratio category at week 176 in prediabetes
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10/15 mg · 176 weeksAs given in this study (human).

    Measurements

    proportion improving WHtR category
    46.4%
    tirzepatide
    proportion improving WHtR category
    9.3%
    placebo

    Source sentences

    Summary
    46.4% improved their category with tirzepatide versus 9.3% with placebo.
    2 context sentences
    Summary · context
    This post hoc analysis included 2,538 participants from the SURMOUNT-1 Phase 3, double-blind, randomized, placebo-controlled trial.
    Summary · context
    Adults with BMI ≥ 30 or ≥ 27 kg/m² and at least one obesity-related complication (ORC), excluding diabetes, were randomized to receive once-weekly tirzepatide (5, 10, or 15 mg) or placebo, alongside a reduced-calorie diet and increased physical activity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.